Multi-centered clinical trial of Longlu Capsule for oligoasthenospermia
Baofang Jin,Xindong Zhang,Zhiqiang Wang,Shudong Lin,Xiaoyu Yang,Guoshou Xia,Dalin Sun,Yongjin Gao,Zhian Tang,Xiangru Li,Zhenyan Zhai
DOI: https://doi.org/10.3969/j.issn.1008-0848.2013.09.012
2013-01-01
Abstract:Objective To observe the efficacy of Longlu Capsule in the treatment of oligoasthenospermia and explore its probable mechanism. Methods Usig the multi-centered randomized controlled study, 360 infertile men with oligoasthenospermia were divided into two groups including the control group (160 cases) and the treatment group (200 cases). The patients in the control group were administrated VitE, 100mg once, bid and the patients in the treatment group were given Longlu Capsule, three pills, tid. After the treatment for 3 months, Semen volume, spermatozoa density, prorsad spermatozoa rate, spermatozoa DFI, seminal SOD, and pregnancy rate were measured. Results A total of 330 patients accomplished the clinical trial. In the treatment group, the index of semen volume, spermatozoa density, prorsad spermatozoa rate, spermatozoa DFI, and seminal SOD, were obviously improved compared to that of pre-treatment (P<0.05). Meanwhile, an obvious amelioration in spermatozoa density, prorsad spermatozoa rate, spermatozoa DFI, seminal SOD, and pregnancy rate were found compared to that of the control group (P<0.05). Conclusion Longlu Capsule can evidently improve the seminal quality and natural pregnancy rate of oligoasthenospermia patients via increasing the anti-oxidant ability.